BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33578374)

  • 1. Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma.
    Kotecha RR; Flippot R; Nortman T; Guida A; Patil S; Escudier B; Motzer RJ; Albiges L; Voss MH
    J Natl Compr Canc Netw; 2021 Apr; 19(4):432-438. PubMed ID: 33578374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry.
    Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
    Cancer Res Treat; 2019 Apr; 51(2):758-768. PubMed ID: 30189720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
    Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
    Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
    Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
    Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Study of Metastatic Renal Cell Carcinoma Patients With Brain Metastases.
    Zapata Laguado M; Paez Quintero H; Gomez A; Varela R
    Cureus; 2023 Jan; 15(1):e34014. PubMed ID: 36811042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
    Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
    PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).
    Marchioni M; Kriegmair M; Heck M; Amiel T; Porpiglia F; Ceccucci E; Campi R; Minervini A; Mari A; Van Bruwaene S; Linares E; Hevia V; Musquera M; D'Anna M; Derweesh I; Bradshaw A; Autorino R; Guruli G; Veccia A; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Palumbo C; Klatte T; Erdem S; Mir MC;
    Eur Urol Oncol; 2021 Apr; 4(2):256-263. PubMed ID: 33384274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
    Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC
    JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study.
    Massari F; Di Nunno V; Guida A; Costa Silva CA; Derosa L; Mollica V; Colomba E; Brandi G; Albiges L
    Clin Genitourin Cancer; 2021 Feb; 19(1):32-40. PubMed ID: 32694008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
    Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
    Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
    Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
    Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
    Vickers MM; Al-Harbi H; Choueiri TK; Kollmannsberger C; North S; MacKenzie M; Knox JJ; Rini BI; Heng DY
    Clin Genitourin Cancer; 2013 Sep; 11(3):311-5. PubMed ID: 23684422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
    Yekedüz E; Karakaya S; Ertürk İ; Tural D; Uçar G; Şentürk Öztaş N; Arıkan R; Hızal M; Küçükarda A; Sever ÖN; Arslan Ç; Can O; Kılıçkap S; Yazgan C; Karadurmuş N; Şendur MA; Çiçin İ; Demirci U; Özgüroğlu M; Öksüzoğlu B; Ürün Y
    Clin Genitourin Cancer; 2023 Feb; 21(1):175-182. PubMed ID: 35970759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.
    Parmar A; Ghosh S; Sahgal A; Lalani AA; Hansen AR; Reaume MN; Wood L; Basappa NS; Heng DYC; Graham J; Kollmannsberger C; Soulières D; Breau RH; Tanguay S; Kapoor A; Pouliot F; Bjarnason GA
    Cancer Rep (Hoboken); 2023 Mar; 6(3):e1763. PubMed ID: 36517084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical study of brain metastasis of renal cell carcinoma.
    Harada Y; Nonomura N; Kondo M; Nishimura K; Takahara S; Miki T; Okuyama A
    Eur Urol; 1999 Sep; 36(3):230-5. PubMed ID: 10450008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.
    Bowman IA; Bent A; Le T; Christie A; Wardak Z; Arriaga Y; Courtney K; Hammers H; Barnett S; Mickey B; Patel T; Whitworth T; Stojadinovic S; Hannan R; Nedzi L; Timmerman R; Brugarolas J
    Clin Genitourin Cancer; 2019 Apr; 17(2):e263-e272. PubMed ID: 30538068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
    de Bruijn RE; Nijkamp J; Noe A; Horenblas S; Haanen JB; Prevoo W; Bex A
    Urol Oncol; 2016 Jun; 34(6):258.e7-258.e13. PubMed ID: 26822077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.